The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
Subscribe To Our Newsletter & Stay Updated
